<bill session="108" type="h" number="4151" updated="2013-07-14T19:02:29-04:00">
  <state datetime="2004-04-02">REFERRED</state>
  <status>
    <introduced datetime="2004-04-02"/>
  </status>
  <introduced datetime="2004-04-02"/>
  <titles>
    <title as="introduced" type="short">Brian Lykins Human Tissue Transplant Safety Act of 2004</title>
    <title as="introduced" type="official">To amend the Public Health Service Act to authorize the Commissioner of Food and Drugs to conduct oversight of any entity engaged in the recovery, screening, testing, processing, storage, or distribution of human tissue or human tissue-based products.</title>
  </titles>
  <sponsor id="400224"/>
  <cosponsors>
    <cosponsor id="400020" joined="2004-04-02"/>
    <cosponsor id="400052" joined="2004-07-22"/>
    <cosponsor id="400055" joined="2004-07-22"/>
    <cosponsor id="400141" joined="2004-07-22"/>
    <cosponsor id="400155" joined="2004-06-09"/>
    <cosponsor id="400164" joined="2004-04-02"/>
    <cosponsor id="400174" joined="2004-04-02"/>
    <cosponsor id="400214" joined="2004-04-02"/>
    <cosponsor id="400259" joined="2004-04-02"/>
    <cosponsor id="400265" joined="2004-04-02"/>
    <cosponsor id="400287" joined="2004-04-02"/>
    <cosponsor id="400296" joined="2004-06-09"/>
    <cosponsor id="400299" joined="2004-04-02"/>
    <cosponsor id="400316" joined="2004-04-02"/>
    <cosponsor id="400320" joined="2004-07-22"/>
    <cosponsor id="400332" joined="2004-04-02"/>
    <cosponsor id="400354" joined="2004-04-02"/>
    <cosponsor id="400409" joined="2004-07-22"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2004-04-02">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2004-04-08">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="identical" session="108" type="s" number="1063"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Commerce"/>
    <term name="Communicable diseases"/>
    <term name="Communication in medicine"/>
    <term name="Cytology"/>
    <term name="Data banks"/>
    <term name="Department of Health and Human Services"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Governmental investigations"/>
    <term name="Health facilities"/>
    <term name="Health information systems"/>
    <term name="Labeling"/>
    <term name="Law"/>
    <term name="Licenses"/>
    <term name="Medical screening"/>
    <term name="Medical tests"/>
    <term name="Packaging"/>
    <term name="Preventive medicine"/>
    <term name="Product safety"/>
    <term name="Science, technology, communications"/>
    <term name="Storage"/>
    <term name="Tissue banks"/>
    <term name="Transplantation of organs, tissues, etc."/>
  </subjects>
  <amendments/>
  <summary>4/2/2004--Introduced.
Brian Lykins Human Tissue Transplant Safety Act of 2004 - Amends the Public Health Service Act to provide for oversight by the Commissioner of Food and Drugs of entities engaged in activities relating to human tissue or human tissue-based products, requiring their registration and authorizing their inspection. Requires the reporting of any adverse incidents. Requires the Commissioner to develop a reporting mechanism and a database to store such information. Allows the Commissioner, in an instance in which this Act is violated, to: (1) issue an order requiring any distributor of a human cell, tissue, or cellular or tissue-based product to recall or destroy such product; (2) condemn, seize, and destroy such product; (3) require a covered entity to cease the activity that resulted in the violation; or (4) suspend or revoke the registration and listing of the covered entity involved.</summary>
</bill>
